Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
With conventional treatments (i.e. iv Ig, steroids) the overall response rate of ITP
secondary to LPD is generally lower than in primary ITP, and usually not higher than 50% (95%
CI 27-72). Eltrombopag which has proved very effective in primary ITP could be effective also
in ITP secondary to LPDs.
This novel ITP specific treatment might spare these patients not only from bleeding risk but
also from toxic or inappropriate cytotoxic therapies, not otherwise demanded by the burden of
the underlying disease.